RxSight, Inc.
Financials
Valuation Metrics
RxSight, Inc.'s Market Cap is $215M. At end of 2025 it was $429M. Ranked #3008 of 3,121 in US market (top 96%), #1374 of 1,463 on NASDAQ (top 94%), #192 of 205 in Health Care Equipment & Services (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $215M | US#3,008/3,121 Sec#192/205 |
| Revenue | $128M | US#2,660/3,121 Sec#177/205 |
| Net Income | $-47M | US—/3,121 Sec—/205 |
| Total Assets | $353M | US#2,882/3,121 Sec#169/205 |
| Net Assets | $263M | US#2,581/3,121 Sec#149/205 |
| Employees | 461 | US#2,306/3,121 Sec#158/205 |
| Value | ||
| P/B | 0.82x | US#249/3,121 Sec#16/205 |
| P/S | 1.69x | US#1,148/3,121 Sec#77/205 |
| FCF Yield | -12.62% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -17.83% | US#2,466/3,121 Sec#149/205 |
| ROA | -13.31% | US#2,717/3,121 Sec#160/205 |
| Op. Margin | -43.20% | US#2,669/3,121 Sec#178/205 |
| Revenue Growth | -18.82% | US#2,683/3,121 Sec#195/205 |
| Financial Health | ||
| Debt Ratio | 33.93% | US#386/3,121 Sec#39/205 |
| Total Debt | $11M | US#2,830/3,121 Sec#185/205 |
| FCF | $-27M | US#2,459/3,121 Sec#167/205 |
| Cash | $13M | US#2,932/3,121 Sec#194/205 |
| Current Ratio | 4.07x | US#569/3,121 Sec#55/205 |
| Performance | ||
| 1Y Return | -45.21% | US#2,807/3,121 Sec#182/205 |
| 1M Return | -15.58% | US#2,876/3,121 Sec#193/205 |
| From 52W High | -60.67% | US#2,914/3,121 Sec#190/205 |
| 1Y MDD | -64.94% | US#2,883/3,121 Sec#181/205 |
| Trading | ||
| Volume | 989,831 shares | US#1,386/3,121 Sec#85/205 |
| Trading Value | $5M | US#2,636/3,121 Sec#170/205 |
| Per Share | ||
| EPS | $-1.13 | US—/3,121 Sec—/205 |
| BPS | $6.36 | US#2,158/3,121 Sec#132/205 |
Company Info
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.